Elix and University of Vienna Enter Joint Research Agreement for AI Drug Discovery

Japanese AI drug discovery company Elix is partnering with the University of Vienna to combine its AI molecular generation platform with the university's advanced NMR spectroscopy. The collaboration will focus on designing novel compounds for 'undruggable' targets in areas like cancer and epigenetic signaling.

This Wire brief sits within Fusion42's coverage of Drug Discovery, and 3 sources have reported it between 29 Jul 2026 and 3 Aug 2026.